{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:32:06Z","timestamp":1787160726078,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Transient intraocular pressure (IOP) spikes after intravitreal injection (IVI) are expected. The higher-volume aflibercept 8\u00a0mg (0.07 mL) formulation has recently entered clinical use, yet its early IOP kinetics\u2014particularly the immediate post-injection trajectory in eyes without known glaucoma or ocular hypertension\u2014remain incompletely characterised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this prospective, non-randomised, single-centre comparative study, 48 eyes of 48 patients received intravitreal aflibercept 8\u00a0mg\/0.07 mL (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200925) or aflibercept 2\u00a0mg\/0.05 mL (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200923). Eyes with any history of glaucoma or ocular hypertension were excluded. IOP was measured at baseline and at 3, 10, and 30\u00a0min after injection using iCare IC200 tonometry. The primary objective was to assess within-group IOP changes from baseline in the 0.07-mL group. A hierarchical fixed-sequence procedure was applied using paired Wilcoxon signed-rank tests with Hodges\u2013Lehmann (HL) estimates and 95% confidence intervals (CIs). Between-group differences were explored using a linear mixed-effects model adjusted for baseline IOP, age, sex, and lens status.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline characteristics were comparable between groups. In the 0.07-mL group, HL pseudo-median IOP changes from baseline were +\u200925.5 mmHg (95% CI 18.5 to 32.0;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) at 3\u00a0min, +\u200911.0 mmHg (95% CI 8.0 to 15.0;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) at 10\u00a0min, and +\u20093.5 mmHg (95% CI 1.5 to 5.5;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002) at 30\u00a0min. Adjusted between-group differences (0.07 mL minus 0.05 mL) were +\u20095.8 mmHg (95% CI 0.3 to 11.3;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.038) at 3\u00a0min, +\u20092.8 mmHg (95% CI\u2009\u2212\u20092.7 to 8.3;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.31) at 10\u00a0min, and +\u20090.2 mmHg (95% CI\u2009\u2212\u20095.3 to 5.7;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.94) at 30\u00a0min. Two eyes in the 0.07-mL group received topical IOP-lowering medication after the 30-minute assessment; no paracentesis was performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In eyes without known outflow disease, intravitreal aflibercept 8\u00a0mg (0.07 mL) was associated with a higher early IOP spike than aflibercept 2\u00a0mg (0.05 mL). However, the pressure increase was transient, and exploratory between-group analyses suggested convergence of IOP levels by 30\u00a0min. By defining the early IOP trajectory in eyes with intact outflow, these data provide a physiological reference for the short-term ocular safety of higher-volume anti-VEGF therapy and a benchmark against which exaggerated or delayed responses in at-risk eyes can be interpreted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Not applicable (observational study).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-026-00906-2","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T12:03:42Z","timestamp":1787141022000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early intraocular pressure kinetics after intravitreal aflibercept 8\u00a0mg (0.07 mL) versus aflibercept 2\u00a0mg (0.05 mL) in nonglaucomatous eyes: a prospective comparative study"],"prefix":"10.1186","volume":"12","author":[{"given":"Annika","family":"Licht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Romanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Mirshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"4","key":"906_CR1","doi-asserted-by":"publisher","first-page":"041006","DOI":"10.1115\/1.4029430","volume":"137","author":"B Coudrillier","year":"2015","unstructured":"Coudrillier B, Pijanka J, Jefferys J, Sorensen T, Quigley HA, Boote C, Nguyen TD. Collagen structure and mechanical properties of the human sclera: analysis for the effects of age. J Biomech Eng. 2015;137(4):041006. https:\/\/doi.org\/10.1115\/1.4029430.","journal-title":"J Biomech Eng"},{"issue":"1","key":"906_CR2","doi-asserted-by":"publisher","first-page":"13248","DOI":"10.1038\/s41598-020-70269-7","volume":"10","author":"VA de Vries","year":"2020","unstructured":"de Vries VA, Bassil FL, Ramdas WD. The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):13248. https:\/\/doi.org\/10.1038\/s41598-020-70269-7.","journal-title":"Sci Rep"},{"issue":"10","key":"906_CR3","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1136\/bjophthalmol-2018-312603","volume":"103","author":"T Felfeli","year":"2019","unstructured":"Felfeli T, Hostovsky A, Trussart R, Yan P, Brent MH, Mandelcorn ED. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial. Br J Ophthalmol. 2019;103(10):1388\u201394. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312603.","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"906_CR4","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1016\/j.ophtha.2015.04.018","volume":"122","author":"KB Freund","year":"2015","unstructured":"Freund KB, Hoang QV, Saroj N, Thompson D. Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab. Ophthalmology. 2015;122(9):1802\u201310. https:\/\/doi.org\/10.1016\/j.ophtha.2015.04.018.","journal-title":"Ophthalmology"},{"issue":"7","key":"906_CR5","doi-asserted-by":"publisher","first-page":"e88617","DOI":"10.7759\/cureus.88617","volume":"17","author":"P Gartaganis","year":"2025","unstructured":"Gartaganis P, Khamis N, Bedan H, Driouich A, Ashraf Z, Osman MOA, S., Younis S. A Comparative Assessment of Intraocular Pressure Changes After Aflibercept 8\u00a0mg and Faricimab-svoa Intravitreal Injections in Wet Age-Related Macular Degeneration. Cureus. 2025;17(7):e88617. https:\/\/doi.org\/10.7759\/cureus.88617.","journal-title":"Cureus"},{"issue":"6","key":"906_CR6","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.ajo.2008.07.007","volume":"146","author":"JE Kim","year":"2008","unstructured":"Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol. 2008;146(6):930\u2013e934931. https:\/\/doi.org\/10.1016\/j.ajo.2008.07.007.","journal-title":"Am J Ophthalmol"},{"key":"906_CR7","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2147\/opth.S64721","volume":"8","author":"R Lemos-Reis","year":"2014","unstructured":"Lemos-Reis R, Moreira-Gon\u00e7alves N, Melo AB, Carneiro AM, Falc\u00e3o-Reis FM. Immediate effect of intravitreal injection of bevacizumab on intraocular pressure. Clin Ophthalmol. 2014;8:1383\u20138. https:\/\/doi.org\/10.2147\/opth.S64721.","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"906_CR8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1097\/ijg.0000000000001894","volume":"30","author":"AM Levin","year":"2021","unstructured":"Levin AM, Chaya CJ, Kahook MY, Wirostko BM. Intraocular Pressure Elevation Following Intravitreal Anti-VEGF Injections: Short- and Long-term Considerations. J Glaucoma. 2021;30(12):1019\u201326. https:\/\/doi.org\/10.1097\/ijg.0000000000001894.","journal-title":"J Glaucoma"},{"key":"906_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-025-01239-7","author":"X Lu","year":"2025","unstructured":"Lu X, Kataoka K, Kumagai M, Nochi Y, Yamamoto A, Ko R, Okada AA. Comparison of intraocular pressure elevation following intravitreal injection of 70 \u00b5l aflibercept 8\u00a0mg. Jpn J Ophthalmol. 2025. https:\/\/doi.org\/10.1007\/s10384-025-01239-7.","journal-title":"Jpn J Ophthalmol"},{"issue":"5","key":"906_CR10","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/bjo-2024-326053","volume":"109","author":"A Paris","year":"2025","unstructured":"Paris A, Volpe G, Perruchoud-Ader K, Casanova A, Menghini M, Grimaldi G. Short-term intraocular pressure changes after intravitreal aflibercept 2\u00a0mg, aflibercept 8\u00a0mg and faricimab: a prospective, comparative study. Br J Ophthalmol. 2025;109(5):600\u20135. https:\/\/doi.org\/10.1136\/bjo-2024-326053.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"906_CR11","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41433-025-03765-7","volume":"39","author":"V Sarao","year":"2025","unstructured":"Sarao V, Veritti D, Bonini F, Martin AA, Lanzetta P. Early intraocular pressure dynamics following aflibercept 8\u00a0mg versus aflibercept 2\u00a0mg: a propensity score-matched analysis. Eye (Lond). 2025;39(10):1933\u20139. https:\/\/doi.org\/10.1038\/s41433-025-03765-7.","journal-title":"Eye (Lond)"},{"issue":"1","key":"906_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/112067211002000124","volume":"20","author":"V Sharei","year":"2010","unstructured":"Sharei V, H\u00f6hn F, K\u00f6hler T, Hattenbach LO, Mirshahi A. Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis). Eur J Ophthalmol. 2010;20(1):174\u20139. https:\/\/doi.org\/10.1177\/112067211002000124.","journal-title":"Eur J Ophthalmol"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-026-00906-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00906-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-026-00906-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:24:14Z","timestamp":1787156654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-026-00906-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1186\/s40942-026-00906-2","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"23 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approved by the Institutional Ethics Committee of the Dardenne Eye Clinic, Bonn (ID 2025004). Written informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"110"}}